[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-460202-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-460202-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advances-in-pancreatic-cancer-early-diagnosis-prevention-and-treatment-the-past-the-present-and-the-future","Advances in Pancreatic Cancer Early Diagnosis, Prevention, and Treatment - The Past, the Present, and the Future","","Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by poor prognosis driven by late diagnosis and therapy resistance. Risk is shaped by both modifiable and non-modifiable factors, including chronic pancreatitis, diabetes mellitus, smoking, obesity, and familial predisposition. Because early symptoms are vague, PDAC is frequently identified at advanced stages, restricting curative options. The review summarizes advances in early detection via biomarkers, imaging, and liquid biopsy; discusses surgery and neoadjuvant approaches to improve resectability; evaluates systemic chemotherapy regimens and emerging targeted and immunotherapy strategies; and outlines future priorities for reliable biomarkers and resistance overcoming.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-pancreatic-cancer-early-diagnosis-prevention-and-treatment-the-past-the-present-and-the-future/460202/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-pancreatic-cancer-early-diagnosis-prevention-and-treatment-the-past-the-present-and-the-future/460202.png","ImageObject",300,407,{"name":42,"@type":43},"Danger Angel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early diagnosis of PDAC difficult?","Question",{"text":63,"@type":64},"Early clinical manifestations are often vague and insidious, so PDAC is frequently diagnosed at an advanced stage, limiting curative treatment options.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What approaches are described for improving early detection?",{"text":68,"@type":64},"Efforts focus on serum biomarkers such as carbohydrate antigen 19-9, imaging modalities, and liquid biopsies; endoscopic ultrasound and magnetic resonance imaging show potential in selected high-risk populations.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatment strategies are highlighted for different disease stages?",{"text":72,"@type":64},"Surgical resection is the only potentially curative option, while neoadjuvant chemotherapy can improve resectability. For locally advanced or metastatic PDAC, combination chemotherapy regimens provide survival benefits, with toxicity remaining a concern.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},460202,1791116036,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":113,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090769052,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","DOI: 10. 3322/caac.70035  \nREVIEW ARTICLE  \nAdvances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future  \nAlessandro Mannucci MD 1,2  | Ajay Goel PhD1,3   \n1Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute at City of Hope, Monrovia, California, USA  \n2Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy  \n3City of Hope Comprehensive Cancer Center, Duarte, California, USA  \nCorrespondence  \nAjay Goel, Department of Molecular Diagnostics and Experimental Therapeutics, City of Hope Beckman Research Institute, 1218 S. Fifth Avenue, Suite 226, Duarte, CA 92010, USA.  \nEmail: [ajgoel@coh.org](ajgoel@coh.org)  \nFunding information  \nNational Cancer Institute and the National Institute of Health, Grant/Award Numbers:  \nCA202797, CA214254, CA271243  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a dismal prognosis, largely because of late-stage diagnosis and therapeutic resistance. PDAC incidence has been rising, with modifiable and non-modifiable risk factors contributing to disease development. Chronic pancreatitis, diabetes mellitus, smoking, obesity, and familial predisposition have been implicated in PDAC pathogenesis. Early clinical manifestations are vague and insidious; therefore, PDAC is often diagnosed at an advanced stage, limiting curative treatment options. Efforts to improve early detection have focused on serum biomarkers (e.g., carbohydrate antigen 19-9), imaging modalities, and liquid biopsies. Endoscopic ultrasound and magnetic resonance imaging have demonstrated potential in identifying early-stage disease in certain high-risk populations. Surgical resection remains the only potentially curative option, but only 15%–20% of patients have resectable disease at diagnosis. Neoadjuvant chemotherapy has emerged as a promising strategy to improve resectability and survival outcomes. For patients with locally advanced or metastatic PDAC, combination chemotherapy regimens such as FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), NALIRIFOX (5-fluorouracil, oxaliplatin, liposomal irinotecan, and leucovorin), and combined gemcitabine/ nanoparticle albumen-bound paclitaxel offer survival benefits, although toxicity remains a concern, especially for platinum-based therapies. Several breakthroughsin molecular profiling have led to the development of targeted therapies, including sotorasib and olaparib. Immunotherapy has shown limited success in PDAC due to its immunosuppressive tumor microenvironment. However, novel combination approaches are under investigation, including quadruplet therapy, immune checkpoint inhibitors with oncolytic viruses, stromal-targeting agents, and personalized neoantigen vaccines. Key priorities for future research include identifying reliable biomarkers for early detection, refining patient selection for targeted therapies, and developing innovative strategies to overcome treatment resistance.  \nKEYWORDS  \nearly detection, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX), gemcitabine, pancreatic ductal adenocarcinoma (PDAC), screening, surveillance, treatment  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCA Cancer J Clin. 2026;e70035.  \n[https://doi.org/10.3322/caac.70035](https://doi.org/10.3322/caac.70035)  \nwi[leyonlinelibrary.com/journal/caac](leyonlinelibrary.com/journal/caac)  \n1 of 30  \nINTRODUCTION  \nPancreatic ductal adenocarcinoma (PDAC) remains a significant public health ","cbCaijYUsR9hDYTq","https://ap.wps.com/l/cbCaijYUsR9hDYTq","pdf",3240173,"English","# Introduction\n# Epidemiology With Increasing Incidence\n# Advances in Early Detection and Risk Stratification\n# Therapeutic Strategies: Surgery and Neoadjuvant Approaches\n# Systemic Treatments and Emerging Targeted/Immunotherapy\n# Future Research Priorities","[{\"question\":\"Why is early diagnosis of PDAC difficult?\",\"answer\":\"Early clinical manifestations are often vague and insidious, so PDAC is frequently diagnosed at an advanced stage, limiting curative treatment options.\"},{\"question\":\"What approaches are described for improving early detection?\",\"answer\":\"Efforts focus on serum biomarkers such as carbohydrate antigen 19-9, imaging modalities, and liquid biopsies; endoscopic ultrasound and magnetic resonance imaging show potential in selected high-risk populations.\"},{\"question\":\"Which treatment strategies are highlighted for different disease stages?\",\"answer\":\"Surgical resection is the only potentially curative option, while neoadjuvant chemotherapy can improve resectability. For locally advanced or metastatic PDAC, combination chemotherapy regimens provide survival benefits, with toxicity remaining a concern.\"}]","Advances in Pancreatic Cancer Early Diagnosis, Prevention, and Treatment - The Past, the Present, and the Future | PDF",1790758010,76,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/6e24a7885dc4ab0aecac067a820b3c44.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/64e30d2474132b823d02691d820072c8.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/eeb5e35289629c439b6564e5a2235d81.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/c8bae782670064cec1d2de167364a8de.webp",980,1287]